Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine — Stella
Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine
Trial locations(42 sites)
France
Amiens CHU, Amiens
Angers CHU, Angers
Avignon CH, Avignon
Bayonne CH, Bayonne
Besançon CHU, Besançon
Brest CHU, Brest
Caen CHU, Caen
CERGY PONTOISE - CH René Dubos, Cergy-Pontoise
Hôpital d'Instruction des Armées PERCY, Clamart
CHU Estaing, Clermont-Ferrand
Corbeil-Essonnes - Ch Sud Francilien, Corbeil-Essonnes
Créteil CHU HENRI MONDOR, Créteil
Dijon CHU, Dijon
Grenoble CHU, Grenoble
Le Mans CH, Le Mans
CHU Lille, Lille
Limoges CHU, Limoges
Lyon sud CHU, Lyon
Marseille IPC, Marseille
Meaux CH de l'Est francilien, Meaux
METZ-THIONVILLE CHR- Hôpital de Mercy, Metz
Montpellier - Chu Saint Eloi, Montpellier
Nantes CHU, Nantes
Nice CHU, Nice
Nimes CHU, Nîmes
Paris La Pitié salpetrière, Paris
Paris Necker, Paris
Paris Saint Louis, Paris
Bordeaux CHU, Pessac
Reims CHU, Reims
Rennes CHU, Rennes
roubaix CH, Roubaix
Centre de Lutte Contre le Cancer H. Becquerel, Rouen
Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez
Saint Quentin CH, Saint-Quentin
ICANS - Institut de cancérologie de strasbourg europe, Strasbourg
Toulouse - IUCT Oncopole - Service d'Hématologie, Toulouse